...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMJ: British medical journal >Treating rheumatoid arthritis with tumour necrosis factor α blockade
【24h】

Treating rheumatoid arthritis with tumour necrosis factor α blockade

机译：治疗类风湿性关节炎与肿瘤坏死系数α封锁

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rheumatoid arthritis is one of the commonest autoimmune diseases, with a prevalence of about 1%. and it is perhaps the most common reversible disability in the Western world. After 10 years, 50% of people with rheumatoid arthritis in employment no longer work, most losing their jobs in the first 12 months after diagnosis. Excessive amounts of the pro-inflammatory cytokines, tumour necrosis factor, TNFα interleukin-1 (IL-1β), and interleukin-6 (IL-6), mediate most of the pathogenic features of rheumatoid arthritis. Infliximab, the chimeric antibody to tumour necrosis factor a, and etanercept a fusion protein p75 tumour necrosis factor α receptor immunoglobulin, have been shown to be very effective in reducing the chronic symptoms and signs of rheumatoid arthritis in patients who fail to respond to conventional treatment with disease modifying drugs. Both these molecules produce response rates which are at least as high as those seen with other treatments given for milder disease. Importantly, these drugs have been shown to be effective in patients who were thought to be resistant to all treatment Before these new drugs such patients were left to deteriorate, resulting in cachexic individuals with destroyed joints, a picture all too familiar to physicians.
机译：类风湿性关节炎是最常见的一种自身免疫性疾病,患病率约1%。残疾在西方世界。类风湿性关节炎患者的50%就业不再工作,大多数失去工作在确诊后的头12个月。大量的促炎细胞因子、肿瘤坏死因子,肿瘤坏死因子αinterleukin-1 (il - 1β),和白细胞介素- 6 (il - 6)、调解的大部分类风湿性关节炎的致病特点。英夫利昔单抗,肿瘤的嵌合抗体坏死因子a,道融合我的肿瘤坏死因子α受体的蛋白质免疫球蛋白,已经被证明是非常慢性症状,有效地减少了类风湿性关节炎的患者的迹象传统治疗无法应对修改疾病药物。生产至少高响应率与其它治疗方法温和的疾病。在患者被证明是有效的认为是对之前所有治疗这些新的药物患者了恶化,导致cachexic个人与破坏关节,一幅太熟悉了内科医生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号